These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30303516)

  • 1. NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma.
    Tarhini AA; Frankel P; Ruel C; Ernstoff MS; Kuzel TM; Logan TF; Khushalani NI; Tawbi HA; Margolin KA; Awasthi S; Butterfield LH; McDermott D; Chen A; Lara PN; Kirkwood JM
    Cancer; 2018 Nov; 124(22):4332-4341. PubMed ID: 30303516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
    Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G
    J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.
    Chen H; Modiano MR; Neal JW; Brahmer JR; Rigas JR; Jotte RM; Leighl NB; Riess JW; Kuo CJ; Liu L; Gao B; Dicioccio AT; Adjei AA; Wakelee HA
    Br J Cancer; 2014 Feb; 110(3):602-8. PubMed ID: 24292447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.
    Strickler JH; Rushing CN; Niedzwiecki D; McLeod A; Altomare I; Uronis HE; Hsu SD; Zafar SY; Morse MA; Chang DZ; Wells JL; Blackwell KL; Marcom PK; Arrowood C; Bolch E; Haley S; Rangwala FA; Hatch AJ; Nixon AB; Hurwitz HI
    BMC Cancer; 2019 Nov; 19(1):1032. PubMed ID: 31675952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.
    Ruff P; Van Cutsem E; Lakomy R; Prausova J; van Hazel GA; Moiseyenko VM; Soussan-Lazard K; Dochy E; Magherini E; Macarulla T; Papamichael D
    J Geriatr Oncol; 2018 Jan; 9(1):32-39. PubMed ID: 28807738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.
    Lambrechts D; Thienpont B; Thuillier V; Sagaert X; Moisse M; Peuteman G; Pericay C; Folprecht G; Zalcberg J; Zilocchi C; Margherini E; Chiron M; Van Cutsem E
    Br J Cancer; 2015 Sep; 113(7):1027-34. PubMed ID: 26355232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin.
    Tarhini AA; Frankel P; Margolin KA; Christensen S; Ruel C; Shipe-Spotloe J; Gandara DR; Chen A; Kirkwood JM
    Clin Cancer Res; 2011 Oct; 17(20):6574-81. PubMed ID: 21880788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer.
    Allen JW; Moon J; Redman M; Gadgeel SM; Kelly K; Mack PC; Saba HM; Mohamed MK; Jahanzeb M; Gandara DR
    J Clin Oncol; 2014 Aug; 32(23):2463-70. PubMed ID: 25002722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.
    Chung C; Pherwani N
    Am J Health Syst Pharm; 2013 Nov; 70(21):1887-96. PubMed ID: 24128964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
    Folprecht G; Pericay C; Saunders MP; Thomas A; Lopez Lopez R; Roh JK; Chistyakov V; Höhler T; Kim JS; Hofheinz RD; Ackland SP; Swinson D; Kopp M; Udovitsa D; Hall M; Iveson T; Vogel A; Zalcberg JR
    Ann Oncol; 2016 Jul; 27(7):1273-9. PubMed ID: 27091810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors.
    Rahma OE; Tyan K; Giobbie-Hurder A; Brohl AS; Bedard PL; Renouf DJ; Sharon E; Streicher H; Hathaway E; Cunningham R; Manos M; Severgnini M; Rodig S; Stephen Hodi F
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aflibercept.
    Ciombor KK; Berlin J; Chan E
    Clin Cancer Res; 2013 Apr; 19(8):1920-5. PubMed ID: 23444216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.
    Coleman N; Stephen B; Fu S; Karp D; Subbiah V; Ahnert JR; Piha-Paul SA; Wright J; Fessahaye SN; Ouyang F; Yilmaz B; Meric-Bernstam F; Naing A
    Cancer Med; 2024 Feb; 13(3):e6877. PubMed ID: 38400671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.
    Bahleda R; Baker J; Massard C; Gadgeel SM; Rogers JE; Izzedine H; Deutsch E; Garris JL; Khan A; Boelle E; Assadourian S; Soria JC; Ajani JA
    Oncology; 2016; 90(1):10-20. PubMed ID: 26492090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study.
    Dorval T; Négrier S; Chevreau C; Avril MF; Baume D; Cupissol D; Oskam R; de Peuter R; Vinke J; Herrera A; Escudier B
    Cancer; 1999 Mar; 85(5):1060-6. PubMed ID: 10091789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).
    Lapeyre-Prost A; Pernot S; Sigrand J; Le Malicot K; Mary F; Aparicio T; Dahan L; Caroli-Bosc FX; Lecomte T; Doat S; Marthey L; Desrame J; Lepage C; Taieb J
    Clin Colorectal Cancer; 2020 Dec; 19(4):285-290. PubMed ID: 32921581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA.
    Ivanova JI; Saverno KR; Sung J; Duh MS; Zhao C; Cai S; Vekeman F; Peevyhouse A; Dhawan R; Fuchs CS
    Med Oncol; 2017 Nov; 34(12):193. PubMed ID: 29103187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma.
    Brennecke S; Deichmann M; Naeher H; Kurzen H
    Melanoma Res; 2005 Dec; 15(6):515-22. PubMed ID: 16314737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.
    Yoshino T; Yamazaki K; Yamaguchi K; Doi T; Boku N; Machida N; Onozawa Y; Asayama M; Fujino T; Ohtsu A
    Invest New Drugs; 2013 Aug; 31(4):910-7. PubMed ID: 23179335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
    Tabernero J; Van Cutsem E; Lakomý R; Prausová J; Ruff P; van Hazel GA; Moiseyenko VM; Ferry DR; McKendrick JJ; Soussan-Lazard K; Chevalier S; Allegra CJ
    Eur J Cancer; 2014 Jan; 50(2):320-31. PubMed ID: 24140268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.